Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies

Abstract Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway continues to lead to the testing of multip...

Full description

Bibliographic Details
Main Authors: Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak, Katarzyna Magiera-Mularz
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Molecular Cancer
Subjects:
PD-1
Programmed death 1
PD-L1
Programmed death ligand 1
CD80
Immune checkpoint blockade
Online Access:https://doi.org/10.1186/s12943-023-01853-4

Internet

https://doi.org/10.1186/s12943-023-01853-4

Similar Items